21:59 , Apr 25, 2019 |  BC Extra  |  Company News

Salix licenses S1P receptor modulator from Mitsubishi

Mitsubishi has found a new partner for its oral S1P receptor modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd. gained exclusive rights Thursday to develop...
20:51 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Anxiety Mouse studies suggest inhibiting KPNA1 or its downstream mediator the S1P receptor could help treat anxiety. In a mouse model of anxiety, systemic KPNA1 knockout or intrahippocampal injection of an shRNA targeting KPNA1...
20:34 , Feb 3, 2017 |  BC Week In Review  |  Company News

Mitsubishi, Biogen deal

Mitsubishi and Biogen terminated a 2015 deal granting Biogen exclusive rights to develop and commercialize amiselimod (MT-1303) worldwide, excluding Asian territories. The small molecule sphingosine 1-phosphate (S1P) receptor functional antagonist has completed Phase II trials...
07:00 , Oct 26, 2016 |  BC Extra  |  Top Story

Biogen reports Tecfidera growth, ends S1P program

In its 3Q16 earnings report, Biogen Inc. (NASDAQ:BIIB) said sales of multiple sclerosis drug Tecfidera dimethyl fumarate grew 10% compared to 3Q15. The company also said it discontinued development of autoimmune candidate amiselimod ( MT-1303...